Navigation Links
MiMedx Announces 2012 Results
Date:3/7/2013

piFix® revenues until well into the second quarter.  Thus, the growth in revenue in the first quarter is expected to be the smallest of the three quarters in 2013.  Based on management's best estimates, the quarterly revenues will be in the following ranges:

1st Quarter:  $10.5
to
$11.5 million
2nd Quarter:  $11.5
to
$13.5 million
3rd Quarter:  $13.5
to
$16.0 million
4th Quarter:  $14.5
to
$19.0 million

Management expects that the Company will be able to continue growing revenue quarter- over-quarter in spite of some degree of cyclicality in the market.  However, the revenue growth quarter-over-quarter will vary significantly depending on the rate at which new sales executives are added particularly to our commercial wound care sales organization.  As previously stated, the timing of the additions will be determined by when Medicare Intermediary coverage is received in each region.

Earnings CallMiMedx management will host a live broadcast of its year end 2012 results conference call on Thursday, March 7, 2013, beginning at 10:30 a.m. eastern time.  A listen-only simulcast of the MiMedx Group conference call will be available online at the Company's website at www.mimedx.com or at www.earnings.com.  A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast.  The replay can also be found on the Company's website at www.mimedx.com or at www.earnings.com.

About the CompanyMiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the frame
'/>"/>

SOURCE MiMedx Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. MiMedx Group to Present at the 6th Annual OneMedForum
2. MiMedx Group to Present at the Stifel Nicolaus 2012 Healthcare Conference
3. CCS Medical Announces Agreement with LifeScan
4. HUYA Bioscience Announces Partnership With Shanghai Zhangjiang Biotech Pharmaceutical Base
5. AVANIR PHARMACEUTICALS ANNOUNCES RESEARCH COLLABORATION WITH DEPARTMENT OF VETERANS AFFAIRS FOR SCREENING PSEUDOBULBAR AFFECT (PBA) SYMPTOMS IN VETERANS WITH TRAUMATIC BRAIN INJURY
6. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Impax Laboratories Inc.
7. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
8. DMH International Announces The Launch of TouchPACS
9. Psyche Systems Announces Availability of Toxicology LIS
10. Jazz Pharmaceuticals Announces Pricing Of Public Offering Of Ordinary Shares By Selling Shareholders
11. DDS Lab Announces Strategic Alliance with United Concordia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
(Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... report results for the fourth quarter of 2013 on Monday, ... scheduled for release after the close of trading. ... a conference call to discuss the operating highlights and financial ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... 2011 Phreesia, the patient check-in company, today ... health records (EHR) software and solutions, has been ... partnership, medical practices nationwide that use both SOAPware ... seamless patient check-in experience. The automated interface between ...
... 18, 2011 Ohio-based AdCare Health Systems, Inc. ... Remedi SeniorCare®, one of the nation,s largest institutional ... services for AdCare,s facilities  that deliver long-term care ... Remedi pharmacy services will include pharmacist ...
Cached Medicine Technology:Phreesia and SOAPware Integrate to Improve Clinical Data and Streamline Workflow at Medical Practices 2Phreesia and SOAPware Integrate to Improve Clinical Data and Streamline Workflow at Medical Practices 3AdCare Health Systems Selects Remedi SeniorCare for Long-Term Care Pharmacy Solutions 2AdCare Health Systems Selects Remedi SeniorCare for Long-Term Care Pharmacy Solutions 3
(Date:4/22/2014)... computational tool developed at the University of Utah (U ... mutations in three separate cases, U of U researchers ... The American Journal of Human Genetics . The ... undiagnosed illnesses and unknown gene mutations by analyzing the ... for genes are made, in individual patients and small ...
(Date:4/22/2014)... cell lung cancer are 70 years of age or ... are not well represented in clinical trials. Therefore, the ... reach evidence based clinical recommendations. , In 2010, the ... Cancer Group along with the International Society for Geriatric ... for elderly patients with non-small cell lung cancer (NSCLC), ...
(Date:4/22/2014)... -- When mothers are exposed to trauma, illness, alcohol ... single molecular trigger in brain cells that can go ... disorder and some forms of autism. , Until now, ... impacted the cells of a developing brain. Past studies ... to alcohol or drug abuse or she experiences some ...
(Date:4/22/2014)... (April 22, 2014) Cedars-Sinai stroke intervention researchers have ... and Stroke, part of the National Institutes of Health, ... multicenter Phase II clinical trial of an experimental drug ... used in combination with recombinant tissue plasminogen activator, or ... ischemic strokes shortly after onset. In laboratory rodent studies, ...
(Date:4/22/2014)... on results of a clinical trial led by ... Drug Administration (FDA) approved a molecularly targeted drug ... has progressed after standard chemotherapy has failed. , ... announced by the manufacturer, Lilly Oncology, of Indianapolis. ... it will be sold under the name Cyramza, ...
Breaking Medicine News(10 mins):Health News:Applying math to biology: Software identifies disease-causing mutations in undiagnosed illnesses 2Health News:Applying math to biology: Software identifies disease-causing mutations in undiagnosed illnesses 3Health News:EORTC and SIOG update expert opinion on management of elderly patients with NSCLC 2Health News:Life stressors trigger neurological disorders, researchers find 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 3Health News:FDA approves first targeted drug for advanced stomach cancer 2
... lead character smokes is not as effective a method as ... the appeal of smoking to , are non-smokers. ... the June issue of the journal Tobacco Control. ... whom were current smokers, aged 12-24 years in Australia, over ...
... found that diabetes is associated with decreases in life expectancy, ... ,The study, published in Archives of Internal Medicine, ... with diabetes at age 50 and older appear not to ... without cardiovascular disease, than individuals without diabetes. ,Globalization ...
... Just a short walk from some of Tokyo's most chic ... for long, if the government gets its way . In ... baskets loaded with their fresh catch at Tsukiji market, minutes ... luxury shops and corporate headquarters. The world's largest ...
... disease in monkeys with the help of human stem cell ... in the Proceedings of the National Academy of Sciences, the ... and grew them into large numbers in the laboratory. ... of monkeys with a severe form of chemically induced Parkinson's ...
... ballet shoe are booming in Britain, where the latest unusual ... environment . Since 2000, Vic Fearn and Company have been ... Coffins". The firm recently expanded their range to ... from the clients," said John Gill, head of the Nottingham, ...
... is dumped in Urali Devachi, about 25 kilometers from the ... villagers . ,Urali Devachi village has been turned into ... the citys nearly five million plus population. ,The ... to Urali Devachi, located on Pune-Saswad road, in 1999. ...
Cached Medicine News:Health News:Diabetes Reduces Life Expectancy, Increases Heart Disease Risk 2Health News:Traders Smell Something Fishy in Tokyo Market Move 2Health News:Traders Smell Something Fishy in Tokyo Market Move 3Health News:To Die For: Rolls-Royce and 'green' Coffins at British Funerals 2
Inquire...
Use the Mo Bio Vortex adapter to process multiple samples at the same time. The adapter holds tubes horizontally to increase cell lysis and mixing efficiency. Ideal for bead beating procedures....
Use the Mo Bio Vortex adapter to process multiple samples at the same time. The adapter holds tubes horizontally to increase cell lysis and mixing efficiency. Ideal for bead beating procedures....
... Mo Bio Vortex Adapter in conjunction with the ... Using the Mo Bio Vortex Adapter is ... Fast Prep machines which offer the same technology. ... centrifuge tubes at one time and will fit ...
Medicine Products: